



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

---

To  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers, Dalal Street  
Mumbai – 400001 1

1 January 2026

**Scrip Code: 524322**

**Subject: Outcome of Board Meeting held on on 1st January 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

We hereby inform that, meeting of Board of Directors of the Company was held at their meeting held today, Thursday, 1st January 2026 5, at the Corporate Office of the Company Corporate Office No:3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai – 600033, has inter alia considered and approved the following business items:

#### **1. Change of Name of the Company**

The Board has approved the proposal to change the name of the Company to better reflect its new business direction and brand identity. This change is subject to the availability of the name from the Ministry of Corporate Affairs and subsequent approval by the shareholders.

#### **2.Strategic Acquisition of Vassmaan Automotive PVT LTD.**

The Board has granted in-principle approval for the acquisition of Vassmaan Automotive PVT LTD. This acquisition is strategic to the Company's diversification into Medical Equipment & EV Components design and manufacturing Sector. It aim to utilize it's capabilities in precision engineering for medical industries.

#### **3. Expansion of Distribution Network**

The Board took on record that the Company has signed an agreement with M/s. MR FRANCHISE to appoint 200 channel partners throughout the country. This initiative is intended to strengthen the Company's market presence and distribution capabilities nationwide.

#### **4. Diversification and Alteration of Main Objects (MOA)**

To facilitate the Company's entry into new high-growth sectors, the Board approved the amendment of the Main Objects clause of the Memorandum of Association (MOA) to include:

- Electric Vehicle (EV) Components manufacturing and distribution.
- Steel manufacturing.
- Solar Energy equipment manufacturing and power generation.



# Kabra Drugs Limited

CIN NO : L02423MP1989PLC005438

Corp. Off : No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai - 600 033.

---

## Shareholder Approval and EGM:

The aforementioned items are subject to the approval of the shareholders. The Board has decided that the date, time, and venue for the Extraordinary General Meeting (EGM), along with the dispatch of the Notice of EGM, will be determined in a subsequent Board Meeting. The same will be intimated to the Stock Exchange separately.

The meeting of the Board of Directors commenced at 5:00 PM and concluded at 6:00 PM.

We request you to take the above information on record.

Yours faithfully,

**For Kabra Drugs Limited**

**Managing Director**  
**DIN: 01895602**

